1. Report Information - Report Title: Weekly Report on Capital Flows of Exchange-Traded Index Funds - Data Date: September 8 - 12, 2025 - Research Institution: Great Wall Securities Industrial Finance Research Institute - Analyst: Jin Ling - Report Date: September 17, 2025 [1] 2. Core View - The report presents the capital flow, fund scale, and weekly price change data of various exchange-traded index funds from September 8 - 12, 2025, covering comprehensive, industry theme, style strategy, enterprise nature, regional, QDII, bond, commodity, and index-enhanced funds. 3. Summary by Category Comprehensive Index Funds - **Fund Performance**: The Shanghai Composite 50 had a fund scale of 15.9456 billion yuan, a weekly increase of 0.99%, and a net weekly capital outflow of 394 million yuan; the CSI 300 had a scale of 98.3449 billion yuan, a rise of 1.51%, and an outflow of 4.095 billion yuan; the CSI 500 had a scale of 14.012 billion yuan, a 3.41% increase, and an inflow of 1.174 billion yuan [6]. Industry Theme Index Funds - **Sector Performance**: The large technology sector had a fund scale of 21.6688 billion yuan, a 5.13% increase, and an outflow of 6.616 billion yuan; the large finance sector had a scale of 12.8483 billion yuan, a 0.92% rise, and an inflow of 11.468 billion yuan; the large health sector had a scale of 10.0161 billion yuan, a 0.50% decline, and an inflow of 6.432 billion yuan [7]. Style Strategy Index Funds - **Style Performance**: The dividend style had a fund scale of 5.9877 billion yuan, a 1.01% increase, and an inflow of 633 million yuan; the growth style had a scale of 730.6 million yuan, a 3.02% increase, and an outflow of 252 million yuan; the value style had a scale of 330.8 million yuan, a 1.11% increase, and an outflow of 102 million yuan [9]. QDII Index Funds - **Overseas Market Performance**: The Nasdaq 100 had a fund scale of 7.8421 billion yuan, a 0.73% increase, and an outflow of 197 million yuan; the S&P 500 had a scale of 2.0837 billion yuan, a 0.69% increase, and an outflow of 38 million yuan; the German DAX had a scale of 975 million yuan, a 0.43% decline, and an inflow of 101 million yuan [11]. Bond Index Funds - **Bond Type Performance**: The 30-year bond had a fund scale of 896.9 million yuan, a 1.18% decline, and an inflow of 149 million yuan; the 10-year bond had a scale of 409 million yuan, a 0.20% decline, and no net inflow; the 5 - 10-year bond had a scale of 3.8952 billion yuan, a 0.26% decline, and an outflow of 302 million yuan [12]. Commodity Index Funds - **Commodity Performance**: Gold had a fund scale of 7.0887 billion yuan, a 2.33% increase, and an inflow of 2.095 billion yuan; soybean meal had a scale of 419.3 million yuan, a 0.75% increase, and an inflow of 12 million yuan; non-ferrous metals had a scale of 74.5 million yuan, a 1.40% increase, and an inflow of 7.7 million yuan [12]. Index-Enhanced Funds - **Index Enhancement Performance**: The Shanghai Composite 50 index-enhanced fund had a scale of 76 million yuan, a 0.99% increase, and no net inflow; the CSI 300 had a scale of 320.9 million yuan, a 1.30% increase, and an outflow of 108 million yuan; the CSI 500 had a scale of 197.8 million yuan, a 2.72% increase, and an inflow of 21.6 million yuan [12].

Group 1: Company Overview - The Chongqing enterprise group was established in 2009, officially commenced production in 2011, and began the second phase of construction in 2018, with the second phase starting production in 2020. The area covers approximately 800 acres, including a chicken farm of about 670 acres [1] - The Hangzhou enterprise group is located in Linping District, Hangzhou, covering around 200 acres, involving oil refining, packaging oil production, rice processing, and central kitchen operations [1] - The company has built a total of 83 production bases nationwide [1] Group 2: Health Products and Innovations - The company’s health products are primarily upgrades of existing products, including low GI rice and plant sterol products from the Taizhou factory, and low GI rice varieties from the Langfang central kitchen [2] - Future plans include launching more health-functional products [2] Group 3: Business Growth and Trends - The Chongqing enterprise group's flour business has shown good growth despite a slight decline in overall flour consumption in the industry, attributed to a refined product classification strategy [2] - The central kitchen food park in Chongqing is performing well, with ongoing negotiations for new clients and partnerships with local advantageous companies to enhance competitiveness [2] Group 4: Central Kitchen Operations - The central kitchen's design is standardized, with a height of approximately 8 meters, allowing flexibility to meet diverse production needs of food enterprises [2] - Clients in the central kitchen are responsible for procuring their own equipment, while the company provides raw materials, logistics, and supply chain services [2] Group 5: Egg Production and Sales - The egg production business is advantageous due to low market concentration, utilizing existing feed resources and sales channels, with a focus on high food safety standards [2] - The Chongqing chicken farm has a current stock of 750,000 hens, with sales channels including traditional supermarkets and local chains [2]

Core Viewpoint - Tianjin Development (00882.HK) announced a partnership agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical, with several investment entities to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1 - The fund will primarily invest in equity of unlisted companies and publicly traded stocks issued or traded in a non-public manner, focusing on the health and biotechnology sectors in China [1] - Lifesun Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund, subject to the terms and conditions of the partnership agreement [1] - The investment areas include innovative drugs, medical devices, in vitro diagnostic devices (IVD), medical services, "CXO" and related pharmaceutical outsourcing services, pharmaceutical-related equipment or consumables, life science instruments and tools, medical technology (including medical big data, AI life sciences, internet healthcare), synthetic biology, bio-agriculture, biomass energy, brain science, medical consumer products, elderly care, traditional Chinese medicine, cell and gene therapy, and other high-quality projects recognized by the investment decision committee [1]

Core Viewpoint - The successful unveiling of the "Medicine and Food Homology and Big Health Academician Workstation" by Dong'e Ejiao and the signing ceremony of cooperation between Liaocheng City and Jiangnan University highlights the importance of collaboration in advancing health and wellness initiatives in the region [1] Group 1: Event Overview - The unveiling ceremony took place in Dong'e County, Shandong, with significant participation from local and academic stakeholders [1] - Shandong Mobile Dong'e Branch received commendation for its excellent network communication support during the event [1] Group 2: Communication Support - A dedicated communication support team was established a week prior to the event to ensure smooth network operations [1] - The team conducted comprehensive network testing, identifying seven weak signal areas and implementing targeted optimizations to enhance network capacity [1] Group 3: Performance and Recognition - The event achieved zero network interruptions and communication failures, providing a seamless experience for users [1] - The commendation letter from the organizer emphasized the company's spirit of "responsibility, coordination efficiency, and multi-department collaboration" [1] Group 4: Future Commitment - Shandong Mobile Dong'e Branch plans to continue leveraging its technological and service advantages to support local digital economic development and provide high-quality communication services for major events [1]

Core Viewpoint - The company is participating in the establishment of a new investment fund with a total scale of 500 million RMB, focusing on various high-potential sectors [1] Group 1: Fund Structure - The company will act as a limited partner, committing 200 million RMB, which represents 40% of the fund's total size [1] - The company's wholly-owned subsidiary, Donghu Investment, will serve as the general partner, contributing 50 million RMB, accounting for 10% of the fund [1] - Other limited partners include Xianning Capital and Xianning Industry, each contributing 125 million RMB, which is 25% of the fund's total size [1] Group 2: Investment Focus - The fund will primarily invest in high-quality enterprises in sectors such as new materials, advanced manufacturing, health and wellness, biomedicine, and electronic information [1]

Core Viewpoint - Renhe Pharmaceutical Co., Ltd. is facing significant challenges in maintaining growth due to intense competition and policy regulations in the pharmaceutical industry, as evidenced by its declining revenue and net profit in the first half of 2025 [1][3]. Financial Performance - The company reported a revenue of approximately 1.975 billion yuan in the first half of 2025, a year-on-year decrease of 16.46% [1]. - The net profit attributable to shareholders was about 290 million yuan, down 13.87% year-on-year, continuing a trend of declining performance over recent years [1][3]. - Since 2019, revenue growth has stagnated, with only a slight increase of less than 500 million yuan and net profit rising by just 29 million yuan over five years [3]. Market Challenges - The decline in performance is attributed to factors such as medical insurance cost control policies, a sluggish macroeconomic environment, and fierce competition in the pharmaceutical e-commerce sector [3]. - The health-related product segment generated revenue of 549 million yuan in the first half of 2025, reflecting a 13.4% decrease, which is even higher than the decline in the pharmaceutical segment [3][4]. Acquisition Strategy - Renhe Pharmaceutical has pursued acquisitions in the health sector since 2021, acquiring 80% stakes in seven companies, aiming to create a comprehensive health product line [3]. - However, the anticipated synergies from these acquisitions have not materialized, with revenue levels reverting to pre-acquisition figures [3][4]. Integration Challenges - The difficulties in cross-industry integration have exceeded expectations, as there are significant differences in channels, operations, and brand logic between pharmaceuticals and health consumer products [4]. - The health market has become highly competitive, with both online and offline channels saturated, making it challenging for the company to stand out despite collaborations with major e-commerce platforms [4]. Financial Health - Although the net cash flow from operating activities increased by 86.14% year-on-year, this was primarily due to reduced cash payments for goods and taxes rather than profit growth [6]. - The company's monetary funds decreased by nearly 60% compared to the end of the previous year, indicating a preference for financial management over reinvestment [6]. Future Outlook - The company is working on several projects, including the digital transformation of health and disinfection product production lines, but progress has not met expectations [6]. - The challenges faced by Renhe Pharmaceutical reflect broader difficulties in the traditional OTC pharmaceutical sector, highlighting the need for comprehensive innovation across products, channels, and organizational capabilities to achieve sustainable growth in a transforming industry [6].

Group 1: Core Insights - The report highlights the capital flow trends in exchange-traded funds (ETFs) during the specified period, indicating a mixed performance across different categories of funds [2][4]. - The total fund sizes and weekly net inflows show significant variations, with the CSI 300 experiencing a net inflow of 9.34 billion yuan, while the STAR 50 saw a net outflow of 135.45 billion yuan [6][7]. Group 2: Fund Performance by Category - The report categorizes funds into major themes, with large technology funds showing a fund size of 216.69 billion yuan and a weekly net inflow of 261.95 million yuan, while large financial funds had a size of 128.48 billion yuan with a slight decline of 1% [7]. - In the health sector, large health funds reported a fund size of 100.16 billion yuan with negligible weekly change, while large consumer funds had a net inflow of 55.83 million yuan [7]. Group 3: Sector and Style Analysis - The report provides insights into style strategies, indicating that growth funds had a size of 73.06 billion yuan with a weekly increase of 6.34%, while value funds reported a size of 33.08 billion yuan with a slight increase of 0.26% [9]. - The report also notes that the dividend strategy funds had a size of 598.77 billion yuan but experienced a weekly decline of 0.78% [9]. Group 4: International Fund Performance - Internationally, the Nasdaq 100 had a fund size of 784.21 billion yuan with a weekly increase of 1.44%, while the S&P 500 reported a size of 208.37 billion yuan with a modest increase of 0.72% [11]. - The report indicates that the Hang Seng Index had a fund size of 191.74 billion yuan with a slight decline of 0.29% [11].

Group 1 - The company plans to establish a partnership with several investment firms to create a new equity investment fund with a total subscription amount of RMB 500 million [1] - The company will contribute RMB 150 million, accounting for 30% of the total fund subscription [1] - The investment focus will be on medical devices, medical equipment, and healthcare services, targeting high-end medical devices, AI healthcare, smart wards, smart operating rooms, hospital information systems, robotic-assisted medical services, high-altitude diffusion oxygen supply, and high-end equipment manufacturing [1]

Core Viewpoint - The company emphasizes its commitment to the pharmaceutical and health products sector, focusing on high-margin proprietary brands and leveraging the brand effect of the China National Pharmaceutical Group [1] Group 1: Company Strategy - The company continues to focus on the health sector, particularly in response to the significant impact of policy adjustments on traditional pharmaceuticals [1] - The company plans to adjust its product offerings by expanding its proprietary products based on patient needs [1] Group 2: Supply Chain and Collaboration - The company aims to enhance its supply chain efficiency through increased collaboration with manufacturers and improved logistics [1] - The company will emphasize related products within the China National Pharmaceutical Group's system to strengthen its market position [1]

Group 1 - In August, private equity firms conducted over 6,000 research activities on A-share companies, reflecting a 200% increase month-on-month, indicating a positive outlook for the market [1] - The pharmaceutical and biotechnology sector became the most favored by private equity firms in August, surpassing the computer sector from July, with 1,095 research activities [1][2] - The electronics, machinery equipment, and power equipment sectors also received significant attention, each with over 400 research activities [1] Group 2 - Leading medical device company Mindray received 117 research activities, making it the most researched A-share company in August [2] - Companies in the electronics sector, such as Crystal Optoelectronics, Feikai Materials, and Anji Technology, saw stock price increases of 33.11%, 23.41%, and 17.24% respectively after receiving intensive research [2] - Smaller private equity firms were particularly active, with Shenzhen Shangcheng Asset leading with 143 research activities [2] Group 3 - Private equity firms focused on "hard technology" and "big health" sectors, emphasizing high elasticity targets and leading companies in niche industries [3] - The surge in research activities in the pharmaceutical and biotechnology sector is attributed to reasonable overall valuations and improved expectations for innovative drug policies and industry fundamentals [3][4] - Research activities were concentrated on companies with core competitiveness and innovation capabilities, indicating a preference for safety margins and certainty in stock selection [4] Group 4 - The recent research trends suggest a high level of interest from private equity firms in sectors like electronics, communications, and computers, which are considered "hard technology" representatives [3][5] - The average position of domestic stock private equity firms was reported at 75.55% as of August 22, indicating a continuous increase in positions over three weeks [5] - Despite fluctuations in the A-share market, private equity firms remain actively engaged in positioning themselves for potential structural investment opportunities [5]